Skip to main content

Table 5 Summary of percent filtered glucose excreted in urine on day 2 by treatment

From: Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus

 

Met BID

RE BID

Met + RE BID

N = 13

N = 13

N = 13

Mean (SD)

1.41 (1.52)

51.3 (7.02)

48.7 (9.87)

Median

0.95

51.8

49.3

Min, Max

0.10, 4.71

38.4, 61.3

35.7, 67.9

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us